ArticleBMC medical research methodology2015
Comparison of different approaches to estimating age standardized net survival.
Article in BMC medical research methodology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Trial
- Article
- Hematologic malignancies burden in China compared with the United States 1990-2021 and projections to 2040.Discover oncology · 2026Article
- Prostate Cancer Incidence, Mortality, and Survival in Switzerland.JAMA network open · 2026Article
- Increased incidence, survival, and registration quality of primary hepato-pancreato-biliary cancers in the Netherlands Cancer Registry.International journal of cancer · 2026Article
- Article
- Monitoring Temporal Trends in Cancer Survival: Choosing Appropriate Standards When Accounting for Age and Other-Cause Mortality Variation Over Time.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Analysis of temporal survival trends: considerations and best practice.BMC medical research methodology · 2025Article
- Improvements in cancer survival in Hungary: a nationwide epidemiology study between 2011-2019 based on a health insurance fund database.Frontiers in oncology · 2025Article
- Mixture and Non-mixture Cure Models for Health Technology Assessment: What You Need to Know.PharmacoEconomics · 2024Article
- Critical survival periods in prostate cancer in Sweden explored by conditional survival analysis.Cancer medicine · 2024Article
- Survival in Thyroid Cancer in Sweden From 1999 To 2018.Clinical epidemiology · 2024Article
- Improving communication of cancer survival statistics-feasibility of implementing model-based algorithms in routine publications.British journal of cancer · 2023Article
- The Impact of Age in the Treatment of Non-comorbid Patients with Rectal Cancer: Survival Outcomes from the National Cancer Database.World journal of surgery · 2023Observational
- Impact of a Prior Cancer Diagnosis on Quality of Care and Survival Following Acute Myocardial Infarction: Retrospective Population-Based Cohort Study in England.Circulation. Cardiovascular quality and outcomes · 2023Article
- Global burden of hematologic malignancies and evolution patterns over the past 30 years.Blood cancer journal · 2023Article
- Cervical Cancer Stage at Diagnosis and Survival among Women ≥65 Years in California.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
- Reference-Adjusted Loss in Life Expectancy for Population-Based Cancer Patient Survival Comparisons-with an Application to Colon Cancer in Sweden.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- Estimating causal effects in the presence of competing events using regression standardisation with the Stata command standsurv.BMC medical research methodology · 2022Article
- Non-parametric estimation of reference adjusted, standardised probabilities of all-cause death and death due to cancer for population group comparisons.BMC medical research methodology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundAge-standardized net survival provides an important population-based summary of cancer survival that appropriately accounts for differences in other-cause mortality rates and standardizes the population age distribution to allow fair comparisons. Recently, there has been debate over the most appropriate method for estimating this quantity, with the traditional Ederer II approach being shown to have potential bias.
methodsWe compare lifetable-based estimates (Ederer II), a new unbiased method based on inverse probability of censoring weights (Pohar Perme) and model-based estimates. We make the comparison in a simulation setting; generating scenarios where we would expect to see a large theoretical bias.
resultsOur simulations demonstrate that even in relatively extreme scenarios there is negligible bias in age-standardized net survival when using the age-standardized Ederer II method, modelling with continuous age or using the Pohar Perme method. However, both the Ederer II and modelling approaches have some advantages over the Pohar Perme method in terms of greater precision, particularly for longer-term follow-up (10 and 15 years).
conclusionsOur results show that, when age-standardizing, concern over bias with the traditional methods is unfounded. We have also shown advantages in using the more traditional and modelling methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.